Opthea Limited Sponsored ADR (OPT) has released an update.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Opthea Limited, listed on NASDAQ and ASX, is advancing its promising treatment, Sozinibercept, which aims to improve vision for millions of patients suffering from wet age-related macular degeneration (AMD). With patents secured until 2034, Sozinibercept presents a substantial market opportunity, potentially revolutionizing a $15 billion global market by enhancing results when used with standard anti-VEGF-A therapies. The company anticipates pivotal trial data in 2025 and is preparing for the potential commercialization of this innovative product.
For further insights into OPT stock, check out TipRanks’ Stock Analysis page.
